Phase III Trial of Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Paclitaxel With or Without Trastuzumab as Adjuvant Treatment for Women With HER-2 Over-Expressing or Amplified Node Positive or High-Risk Node Negative Breast Cancer

Trial Profile

Phase III Trial of Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Paclitaxel With or Without Trastuzumab as Adjuvant Treatment for Women With HER-2 Over-Expressing or Amplified Node Positive or High-Risk Node Negative Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 24 Aug 2017

At a glance

  • Drugs Trastuzumab (Primary) ; Cyclophosphamide; Doxorubicin; Paclitaxel; Tamoxifen
  • Indications Adenocarcinoma; Advanced breast cancer; Early breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 02 Jun 2017 Results (n=1392) assessing effect of age, immune landscape on long term outcome of HER2+ patients, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 05 Apr 2017 Results (n= 1280) assessing immune related genes (OX40) associated with poor outcome in N9831 trial, presented at the 108th Annual Meeting of the American Association for Cancer Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top